


Corporate Update





Disclaimer

This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto.


Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.



Agenda

1. Governance Principles at Evotec
2. Business Update





Full compliance with EU Market Abuse Regulation (MAR)

State-of-the art compliance framework & good governance

Insider-Policy

- Revised dedicated Insider-Policy (supplementary to Code of Conduct) in place since NASDAQ IPO in November 2021
- Approved by MB and SB and published on Website (Code of Conduct -> [Link](#))
- Clear definitions of what is an insider information and consequential trade prohibition
- Clear definition and explanation of Black Out Periods (30 days prior to announcement of quarterly/annual results)
- Mandatory clearance proceeding obliged to prior clearance of any trade in Company shares with General Counsel

Code of Conduct (CoC)

- CoC sets standards for general compliance with insider trading laws and prevention of conflicts of interest
- Approved by MB and SB and published on Website (Code of Conduct -> [Link](#))

Insider lists

- Insider lists pursuant Article 18 MAR available and managed through state-of-the art electronic tool


Shareholdings reconciliation

- General Counsel reaches out to SB and MB members regularly in December to confirm shareholdings, LTI, RSP as of 31 Dec.



Agenda

1. Governance Principles at Evotec
2. Business Update





Focusing on execution

Business update

Strategy unchanged

- Strategy has been developed TOGETHER and is supported unanimously by Management Board and Supervisory Board

Business continuity not affected

- High customer satisfaction unchanged; Ability to generate new business unaffected based on commercial organisation with 100+ professionals and Evotec's promise for efficient execution and higher probability of success
- Just – Evotec Biologics is on track to become a meaningful earnings contributor in the coming years; Sandoz collaboration unfolding according to plan; Hiring of personnel to build basis for 2025 and beyond; Opening of J.POD Toulouse in September; Capital Markets Day on 10 October in Toulouse
- Market outlook including funding of biopharma R&D turning more positive

Guidance 2023 confirmed

- Trends seen in Q3 have continued over the course of Q4 2023

Outlook 2025 unchanged

- In light of robust underlying demand and multiple layers to improve efficiency it is all about execution in Base Business and at Just – Evotec Biologics. Risk-adjusted contribution from Milestone payments subject to scientific results.



Robust underlying performance

Guidance 2023

	Guidance 2023 ⁴	YE 2022	Comments
Group revenues (at constant fx-rates ¹)	€ 750 – 790 m (€ 765 – 805 m)	€ 751.2 m	At least stable despite approx. € 70 m one-off effect
Unpartnered R&D ²	€ 60 – 70 m	€ 69.9 m	Stable
Adjusted EBITDA ³ (at constant fx-rates ¹)	€ 60 – 80 m (€ 70 – 90 m)	€ 101.0 m ³	Mitigation of large parts of approx. € 90 m one-off effect


***Approx. € 200 m continued investments for enabling and supporting growth
(e.g., capacity expansion in biologics manufacturing, iPSC, E.MPD, CO₂e reduction...)***




Our mid-term aspirations are unchanged

2020-2025 estimated key performance indicator goals¹


Group revenues
in € m




Adjusted group EBITDA
in € m



Unpartnered R&D
in € m



Co-owned projects²





Upcoming important dates

Financial calendar 2024

FY 2023 results / Sustainability Report

24 April 2024

Q1 2024 results

22 May 2024

Annual General Meeting 2024

10 June 2024

H1 2024 results

14 August 2024


Capital Markets Day (Toulouse)

10 October 2024

9M 2024 results

06 November 2024

QUESTIONS
AND ANSWERS



*Volker Braun
EVP Global Head of Investor Relations & ESG*

*+49 (0) 151 1940 5058 (m)
volker.braun@evotec.com*
